Multicenter pahse II trial of neoadjuvant goserelin acetate and tamoxifen treatment for premenopausal ER-positive and HER2-negative breast cancers

INTERVENTION: Treatment with goserelin acetate (3.6mg, q4w) and tamoxifen (20mg/day) for 24 weeks. CONDITION: Premenopausal breast cancer PRIMARY OUTCOME: clinical response rate SECONDARY OUTCOME: Pathological response, Rate of breast conserving surgery, safety, disease free survival INCLUSION CRITERIA: 1. Histologically or cytologically confirmed premenopausal breast cancer (female between 20 and 55 years old) 2. Stage I‐III (TNM) 3. Estrogen receptor positive (positive cells were more than 10%) 4. HER 2 negative (IHC score 0, 1 or 2 and FISH‐negative) 5. Containing measurable tumor 6. PS: 0‐1 (ECOG) 7. Signed written informed consent